- $1.05m
- $9.58m
- $4.35m
Brief: Navidea Biopharmaceuticals Rejects Prophase Labs Offer To Acquire Certain Assets Of Navidea
Brief: Prophase Labs Inc Reports Quarterly Earnings Per Share Of $0.03
Prophase Labs Inc expected to post a loss of 9 cents a share - Earnings Preview
Therapy In Preclinical Studies Attacking Range Of Hard-To-Treat Cancers, Including Lung And Gastric Cancers
Brief: Prophase Labs CEO Ted Karkus Named One Of Inc Magazine’s 10 Most Innovative Healthcare Leaders To Watch In 2023
Prophase Labs Inc reports results for the quarter ended in December - Earnings Summary
Brief: Prophase Labs Announces Record Financial Results For The Year Ended December 31, 2022
Prophase Labs Inc expected to post earnings of 3 cents a share - Earnings Preview
Brief: Prophase Labs Announces New $6 Mln Share Buyback Program
Brief: Prophase Labs’Nebula Genomics Subsidiary Introduces Lowest Ever Ngs Pricing Of $249 For Its Whole Genome Sequencing Dna Test
Brief: Prophase Labs Announces Collaboration For Development Of Pre-Cancer Diagnostic Screening Test
Brief: Prophase Labs Announces Plans To Initiate Clinical Trial Of Equivir
Brief: Prophase Labs Announces Plans For Major Expansion Of Its Pharmaloz Manufacturing, Inc. Subsidiary To Meet Growing Demand
Therapy Program
Brief: Prophase Labs Acquires BE-Smart Esophageal Pre-Cancer Diagnostic Screening Test
Brief: Prophase Labs Acquires Rights To Novel Esophageal Cancer Test
Prophase Labs Inc reports results for the quarter ended in September - Earnings Summary
Prophase Labs Inc expected to post earnings of 19cents a share - Earnings Preview
Brief: Prophase Labs Announces Collaboration With Dana-Farber Cancer Institute